Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Janus Kinase (JAK) Inhibitors Global Market Report 2024, Featuring Key Players Pfizer, Merck, AbbVie, Novartis, Sanofi, Bristol Myers Squibb, GSK, Takeda, Eli Lilly and Gilead Sciences


DUBLIN, March 4, 2024 /PRNewswire/ -- The "Janus Kinase (JAK) Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

The latest research on the global Janus Kinase (JAK) inhibitors market underscores a substantial growth trajectory, with an anticipated climb from $17.29 billion in 2023 to a projected $20.41 billion in 2024, marking a striking compound annual growth rate (CAGR) of 18.1%.

This expansion echoes the increasing recognition of the JAK-STAT signaling pathway's significance in numerous diseases, the surge in autoimmune disorder prevalence, along with technological breakthroughs in both targeted therapies and diagnostics for these conditions.

Further magnifying this growth, the market is expected to accelerate to reach an impressive $39.92 billion by 2028 at an 18.3% CAGR. This prognosis is fueled by the burgeoning biopharmaceutical R&D, fast-paced regulatory approvals, and broader clinical trial scopes for JAK inhibitor medications. Additionally, the thrust towards more individualized treatment options in the form of personalized and precision medicine, combined with digital health innovations, has set the stage for this market's robust health.

The steady rise in autoimmune diseases propels the demand for JAK inhibitors. These medications bring considerable therapeutic benefits by altering immune responses, reducing inflammation, and relieving symptoms, particularly in diseases such as rheumatoid arthritis and psoriasis?with the latter affecting millions across the globe.

With the growth of personalized medicine, where treatments are customized based on genetic and molecular profiles, JAK inhibitors have found a pivotal role in providing effective treatment for autoimmune diseases and certain cancers.

Pharmaceutical companies are incessantly innovating with JAK inhibitor product offerings to solidify market positions. A recent FDA approval of a JAK inhibitor for the treatment of COVID-19 in hospitalized patients on varying oxygen support levels is an exemplar of such innovation.

Topical formulations have emerged as an inventive approach to medication delivery, with recent FDA approvals heralding a new era of treatment options for conditions such as vitiligo?a testament to the market's evolving landscape.

Key Market Players and Expansions

Major players continue to drive innovation, notable in recent acquisitions, such as Sun Pharma Ltd.'s strategic purchase, adding a promising JAK inhibitor for alopecia areata to their portfolio.

The North American region currently holds the largest market share, with Asia-Pacific identified as the fastest-growing region throughout the forecast period. The wide spectrum of JAK inhibitors, their applications, and the distribution channels reflect a well-diversified and dynamic market landscape.

The research outlines key segments and trends, providing a comprehensive analysis of the Janus kinase (JAK) inhibitors market, with an in-depth review of the current and future market scenario. Industry stakeholders and participants can expect a detailed exploration of market dynamics, regional analysis, and competitive strategies integral to understanding and capitalizing on market opportunities.

The Janus kinase (JAK) inhibitors market research offers an overview of the field, indispensable for those seeking to consolidate their market stance or venture into this burgeoning market space.

Key Markets Covered:

For more information about this report visit https://www.researchandmarkets.com/r/g0hpf8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected] 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

SOURCE Research and Markets


These press releases may also interest you

at 13:00
Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of...

13 avr 2024
Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver....

13 avr 2024
MyAdvisor, a holistic wellness technology company, has been awarded the 2023-2024 Platinum Level Bell Seal...

13 avr 2024
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDEtm) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data...

13 avr 2024
On Apr. 11, 2024, VITAL HealthCare, one of the 5 core business divisions of the VITAL Group, marked a stunning debut at the 89th China International Medical Equipment Fair (CMEF) in Shanghai. Drawing on the Group's core competence in R&D and its...

12 avr 2024
The report titled "STD Testing Market by Type (Blood Tests, Lumbar Puncture, Swab Tests), Product Type (Instruments, Reagents & Kits), Test Settings, Indication, End-user - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...



News published on and distributed by: